Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
GA Knoll, MB Kokolo, R Mallick, A Beck… - Bmj, 2014 - bmj.com
Objective To examine risk of malignancy and death in patients with kidney transplant who
receive the immunosuppressive drug sirolimus. Design Systematic review and meta …
receive the immunosuppressive drug sirolimus. Design Systematic review and meta …
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
D Fantus, NM Rogers, F Grahammer… - Nature Reviews …, 2016 - nature.com
The mTOR pathway has a central role in the regulation of cell metabolism, growth and
proliferation. Studies involving selective gene targeting of mTOR complexes (mTORC1 and …
proliferation. Studies involving selective gene targeting of mTOR complexes (mTORC1 and …
[HTML][HTML] Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation
L Liefeldt, S Brakemeier, P Glander, J Waiser… - American journal of …, 2012 - Elsevier
Donor-specific HLA antibodies (DSA) have a negative impact on kidney graft survival.
Therefore, we analyzed the occurrence of DSA and antibody-mediated rejection (AMR) in …
Therefore, we analyzed the occurrence of DSA and antibody-mediated rejection (AMR) in …
CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor–based regimen versus a CNI-based regimen: a systematic review and meta …
Results We included 28 randomized, controlled trials with 6211 participants classified into
comparison 1: mTOR inhibitor versus calcineurin inhibitor and comparison 2: mTOR inhibitor …
comparison 1: mTOR inhibitor versus calcineurin inhibitor and comparison 2: mTOR inhibitor …
[HTML][HTML] A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney …
WH Lim, J Eris, J Kanellis, B Pussell, Z Wiid… - American Journal of …, 2014 - Elsevier
This was a systematic review of randomized controlled trials comparing delayed conversion
of mammalian target of rapamycin inhibitors (mTORi) for calcineurin inhibitors (CNIs) versus …
of mammalian target of rapamycin inhibitors (mTORi) for calcineurin inhibitors (CNIs) versus …
[HTML][HTML] Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials
DC Brennan, C Legendre, D Patel, K Mange… - American Journal of …, 2011 - Elsevier
Everolimus (EVR) in heart and renal transplant (RTx) recipients may be associated with a
decreased incidence of cytomegalovirus (CMV). A detailed analysis of the association …
decreased incidence of cytomegalovirus (CMV). A detailed analysis of the association …
[HTML][HTML] Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study
K Budde, F Lehner, C Sommerer, P Reinke… - American Journal of …, 2015 - Elsevier
ZEUS study was an open-label, 12-month, multicenter study in which 300 de novo kidney
transplant recipients were randomized to continue receiving cyclosporine (CsA) or convert to …
transplant recipients were randomized to continue receiving cyclosporine (CsA) or convert to …
[HTML][HTML] Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta‐analysis
D Sawinski, J Trofe‐Clark, B Leas, S Uhl… - American Journal of …, 2016 - Elsevier
Despite their clinical efficacy, concerns about calcineurin inhibitor (CNI) toxicity make
alternative regimens that reduce CNI exposure attractive for renal transplant recipients. In …
alternative regimens that reduce CNI exposure attractive for renal transplant recipients. In …
BKV, CMV, and EBV interactions and their effect on graft function one year post-renal transplantation: results from a large multi-centre study
A Blazquez-Navarro, C Dang-Heine, N Wittenbrink… - …, 2018 - thelancet.com
Abstract Background BK virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV)
reactivations are common after kidney transplantation and associated with increased …
reactivations are common after kidney transplantation and associated with increased …
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients
Cytomegalovirus (CMV) infection and disease are major complications in the renal
transplant recipient. The occurrence of CMV is associated with acute rejection, allograft …
transplant recipient. The occurrence of CMV is associated with acute rejection, allograft …